Published by:  One Zero  Written by:  Emily Mullin Antiretroviral drugs make HIV manageable, but gene therapies could eliminate the virus altogether — provided the treatments can be made safe and economical In the mid-1990s, scientists made a curious but remarkable discovery: A man named Stephen Crohn seemed virtually immune to HIV. In the years before that discovery,…

Published by: Montgomery Magazine  | Issue:  August – September 2019, Page 42 Written by: Jeff Thoreson | Photograph by: Kevin Allen A 3D RENDERING OF HIV VIRUS IN BLOOD STREAM Jeffrey Galvin has been a computer nerd since the seventh grade. Way back in the 1970s era of mainframes, he became interested not so much…

Published by: C&EN on May 12, 2019, In Volume 97, Issue 19.  Written by: Megha Satyanarayana Lionel Hillard’s boss asked him to come into his office. It was the late 1980s in Dallas. The then 29-year-old was a medical assistant at a busy clinic with a room full of patients. But the doctor who ran…

Published by: Site Selection, Digital Edition, May 2019 Issue.  Written by: Gary Daughters Jeff Galvin, founder and CEO of Rockville, Maryland’s American Gene Technologies, speaks of cellular gene therapy with the zeal of an evangelist. “I believe we’re on the eve of a gene and cell therapy revolution that will completely disrupt the traditional drug…

Published by: The Wall Street Journal.  Written by: Betsy McKay Updated: April 17, 2018 11:09 am ET Financial disclosures detail steps Robert Redfield has taken; ethics office found him to be in compliance The new director of the Centers for Disease Control and Prevention resigned positions at four entities, sold stock and forfeited options in…

Newsletter Vol. 29, No. 18, Pg. 2 January 26, 2018 On January 26, 2018, BioWorld, The Daily Biopharmaceutical Newscource, published this story:   American Gene Technologies International Inc. (AGT), of Rockville, Md., disclosed completion of the pilot runs of its HIV cure automated cell processing protocol. That completes a key milestone of the firm’s planned…

Issue: October 2017, Posted Date: 10/2/2017 INTRODUCTION Gene therapy has been emerging for 30 years with the promise of more effectively treating and curing diseases. The basic technology initially used an engineered virus or viral vector to deliver a normal gene to overcome loss of function due to an inherited dysfunctional gene. Vector constructs did not result in…

This biotech company has proprietary technology and therapeutic protocols that are on track to functionally cure HIV-infection and make patients impervious to the HIV virus. AGT’s Protocol AGT is an emerging gene and cell therapy company with an enhanced lentiviral platform capable of addressing a broad range of large and orphan indications including infectious diseases,…

WHY GENE THERAPY COST ESTIMATES ARE WRONG – AN OP-ED FROM AGT CEO, JEFF GALVIN Last week, a colleague and I hosted our first ever Reddit AMA and were intrigued with a question posed by one /u/marefo.   So much so that I felt compelled to dive headfirst into the issue. Gene therapeutics which functionally cure diseases are…

Anyone who has experienced the death of a loved one from a terrible illness can appreciate the life mission of Mr. Jeff Galvin, CEO of American Gene Technologies (AGT). Armed with a bachelor’s degree in Economics from Harvard University, Jeff and AGT work to develop new technologies to find cures for many life-threatening diseases, including…